安慰剂反应荟萃分析:胆汁淤积性瘙痒现代治疗随机对照试验的系统评价与荟萃分析
该研究系统检索并荟萃分析了13项安慰剂对照试验(共548例),评估胆汁淤积性瘙痒现代治疗中安慰剂反应。结果显示安慰剂组瘙痒强度显著下降,标准化均数变化总体为-0.49,中重度为-0.57;应答率分别为30.0%和27.4%。不同结局工具下安慰剂改善幅度存在差异,可能影响治疗效应评估与试验设计。
要点
- 安慰剂组瘙痒强度较基线显著下降,中重度患者标准化均数变化为-0.57。
- 中重度患者NRS平均降低-1.62,但WI-NRS变化-0.65无统计学意义。
- 不同结局工具下安慰剂改善幅度不同,可能影响治疗效应解读。
核心结论
- 胆汁淤积性瘙痒现代治疗试验中安慰剂相关改善幅度因结局工具而异,可能影响治疗效应估计与解读。
研究设计与样本
- 系统评价与荟萃分析,纳入评估回肠胆汁酸转运体抑制剂或PPAR激动剂的安慰剂对照试验,检索截至2026年3月,补充检索2026年7月11日。
- 共纳入13项试验,548例患者,采用随机效应模型(Hartung-Knapp调整)及荟萃回归。
主要发现
- 安慰剂组瘙痒强度在随访至52周内较基线显著下降,总体标准化均数变化为-0.49(95%CI -0.72至-0.27)。
- 中重度瘙痒患者标准化均数变化为-0.57(95%CI -0.81至-0.33),总体应答率为30.0%,中重度为27.4%。
- 中重度患者NRS平均降低-1.62,WI-NRS变化-0.65无统计学意义;PBC-40瘙痒域降低-2.02,总分降低-9.13,5-D瘙痒变化无统计学意义。
- 所有评估的调节因素均无统计学意义。
关键数值与推荐
- 主要结局包括瘙痒强度标准化均数变化、安慰剂应答率及NRS与WI-NRS平均差。
- 次要结局包括PBC-40和5-D瘙痒评分。
临床怎么用
- 在解读胆汁淤积性瘙痒试验结果时需考虑安慰剂反应,尤其不同结局工具下改善幅度存在差异。
- 未来试验设计可参考本研究的安慰剂反应数据选择终点及设定假设。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial-level moderators in randomized controlled trials of contemporary therapies. METHODS: We performed a systematic review and meta-analysis of placebo-controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst-Itch NRS (WI-NRS) scores. Secondary outcomes included PBC-40 and 5-D Itch scores. We used random-effects models with Hartung-Knapp adjustment and meta-regression. RESULTS: Thirteen trials (n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow-up periods of up to 52 weeks. The pooled SMC was -0.49 (95% CI, -0.72 to -0.27) overall, and -0.57 (95% CI, -0.81 to -0.33) for moderate-to-severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate-to-severe). In moderate-to-severe patients, NRS showed a significant mean reduction of -1.62, whereas the WI-NRS change (-0.65) was not statistically significant. Significant reductions occurred in the PBC-40 itch domain (-2.02) and overall score (-9.13), while 5-D Itch changes were non-significant. None of the evaluated moderators were statistically significant. CONCLUSIONS: The magnitude of placebo-associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic-pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. TRIAL REGISTRATION: PROSPERO registration number: CRD420261385974.
引用
- Silveira IB, Süffert LC, Leite GAPD, et al. Meta-Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aliment Pharmacol Ther. 2026. PMID: 42786733. doi:10.1111/apt.70915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。